News

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical ...
Merkel Cell Carcinoma Pipeline Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...
Head and Neck Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...
pharmaphorum3d
Sun Pharma buys Checkpoint and its new cancer drug
Sun Pharma has agreed a takeover deal with US biotech Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running low on cash. The Indian pharma group ...
MPR2d
April 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on ...
American Association of Individual Investors3d
Why TG Therapeutics, Inc.’s (TGTX) Stock Is Down 12.53%
TG Therapeutics, Inc.’s TGTX share price has dipped by 12.53%, which has investors questioning if this is right time to buy.
Yahoo Finance15d
Checkpoint Therapeutics, Inc. (CKPT)
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE ...